Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: A translational study

British Journal of Cancer

Volumn 97, Issue 11, 2007, Pages 1499-1504

  Gunelli, R ^a   Bercovich, E ^a   Nanni, O ^b   Ballardini, M ^b   Frassineti, G L ^b   Giovannini, N ^b   Fiori, M ^a   Pasquini, E ^c   Ulivi, P ^b   Pappagallo, G L ^d   Silvestrini, R ^a   Zoli, W ^b  

^a MORGAGNI PIERANTONI HOSPITAL   (Italy)

^b DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^c Cervesi Hospital   (Italy)

^d PF Calvi Hospital   (Italy)

Author keywords

BCG refractory; Bladder cancer; Endovesical instillation; Gemcitabine

Indexed keywords

ANTIPYRETIC AGENT; BCG VACCINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; GEMCITABINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTEREMIA; BLADDER CANCER; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CYSTECTOMY; CYSTOSCOPY; CYTOLOGY; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DYSURIA; FEBRILE NEUTROPENIA; FEMALE; HEMATURIA; HUMAN; HUMAN CELL; HYPERTHERMIA; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; POLLAKISURIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; URINE INCONTINENCE;

ADMINISTRATION, INTRAVESICAL; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TECHNOLOGY TRANSFER; URINARY BLADDER NEOPLASMS;

EID: 36448971307     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604074     Document Type: Article

References (25)

1. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN (1991) A Phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9: 491-498
2. Bartoletti R, Cai T, Gacci M, Giubilei G, Viggiani F, Santelli G, Repetti F, Nerozzi S, Ghezzi P, Sisani M, TUR (Toscana Urologia) Group (2005) Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase 2 prospective multicenter study. Urology 66: 726-731
3. Campodonico F, Canepa G, Capponi G, Bozzo L, Maffezzini M (2005) Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability. Anticancer Res 25: 2381-2384
4. Cozzi PJ, Bajorin DF, Tong W, Nguyen H, Scott J, Heston WD, Dalbagni G (1999) Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. Clin Cancer Res 5: 2629-2637
5. Dalbagni G, Russo P, Bochner B, Ben-Porat L, Sheinfeld J, Sogani P, Donat MS, Herr HW, Bajorin D (2006) Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 24: 2729-2734
6. Dalbagni G, Russo P, Sheinfeld J, Mazumdar M, Tong W, Rabbani F, Donat MS, Herr HW, Sogani P, dePalma D, Bajorin D (2002) Phase I trial of intravesical gemcitabine in Bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 20: 3193-3198
7. De Berardinis E, Antonini G, Peters GJ, Loves WJ, Van der Born K, Codacci-Pisanelli G, Di Silverio F (2004) Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation. BJU Int 93: 491-494
8. Epstein J, Amin M, Reuter V, Mostofi F (1998) The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Path 22: 1435-1448
9. Gontero P, Casetta G, Maso G, Sogni F, Pretti G, Zitella A, Frea B, Tizzani A (2004) Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol 46: 339-343
10. Kern DH, Morgan CR, Hildebrand-Zanki SU (1988) In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II). Cancer Res 48: 117-121
11. Kohjimoto Y, Iba A, Shintani Y, Uekado Y, Shinka T (2005) Treatment of Bacillus Calmette-Guerin refractory superficial bladder cancer: further intravesical therapy. Hinyokika Kiyo 51: 533-538
12. Laufer M, Ramalingam S, Schoenberg MP, Haisfield-Wolf ME, Zuhowski EG (2003) Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol 21: 697-703
13. Li J, Juliar B, Yiannoutsos C, Ansari R, Fox E, Fisch MJ, Einhorn LH, Sweeney CJ (2005) Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol 20: 1185-1191
14. Lorusso V, Pollera CF, Antimi M, Luporini G, Gridelli C, Frassineti GL, Oliva C, Pacini M, De Lena M (1998) A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 34: 1208-1212
15. Malmstrom P (2000) Improved patient outcomes with BCG immunotherapy vs. chemotherapy: Swedish and worldwide experience. Eur Urol 37: 16-20
16. Malmstrom PU, Wijkstrom H, Lundhholm C, Wester K, Busch C, Norlen BJ (1999) Five-year followup of a randomized prospective study comparing mitomycin C and Bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 161: 1124-1127
17. Oosterlinck W, Van der Meijden A, Sylvester R, Böhle E, Rintala E, Solsona Narvón E, Lovel B (2006) European Association of Urology (EAU): Guidelines on TaT1 (non muscle-invasive) bladder cancer (2006) - www.uroweb.org/fileadmin/user_upload/Guidelines/05%20TaT1%20Bladder%20Cancer.pdf
18. Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F (1998) In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol 41: 385-390
19. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10
20. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxic assay for anticancer drug screening. J Natl Cancer Inst 13: 1107-1112
21. Sobin LH, Wittekind CH (eds) (1997) TNM Classification Malignant Tumours 5th edn. John Wiley & Sons, Inc: New York
22. Sylvester RJ, van der Meijden AP, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168: 1964-1970
23. Von Der Maase H, Seugelov L, Roberts JT, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M (2005) Long-term survival of a randomized trial comparing gemcitabine plus cisplatin with methotrexate- vinblastine-doxorubicin plus cisplatin in patients with bladder cancer. J Clin Oncol 23: 4602-4608
24. Zoli W, Ricotti L, Tesei A, Barzanti F, Amadori D (2001) In vitro preclinical models for a rational design of chemotherapy combinations in human tumors. Crit Rev Oncol Hematol 37: 69-82
25. Zoli W, Ricotti L, Tesei A, Ulivi P, Gasperi Campani A, Fabbri F, Gunelli R, Frassineti GL, Amadori D (2004) Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro. Clin Cancer Res 10: 1500-1507